NCPA supports drug disposal bills, makes approval recommendations
ALEXANDRIA, Va. A group representing the nation’s independent pharmacies heralded two pieces of legislation that pertain to the safe disposal of prescription drugs.
The National Community Pharmacists Association announced its support of legislative efforts made by the House of Representatives and the Senate, which passed their respective drug disposal bills Wednesday and last month. NCPA also added that it was “a giant step forward to allow for controlled substances, which had previously been precluded from any disposal programs, to be included.”
The lobbying group did, however, express concern that neither bill passed by the legislative bodies will provide liability protections for participating pharmacies nor adequate funding mechanisms or grant programs to assist in the cost of responsible collection. These concerns were conveyed to the House prior to the vote, NCPA said.
“Independent community pharmacists are uniquely positioned to help Americans get rid of expired and unused prescription drugs,” said Joseph Harmison, NCPA president and pharmacy owner. “That’s why over 1,000 member pharmacies are now engaged in a successful drug disposal programs with Sharps Compliance Inc.”
ScriptPro becomes pharmacy automation systems provider for NIH
MISSION, Kan. The National Institutes of Health has retained ScriptPro as a provider of pharmacy automation systems, ScriptPro said.
The NIH, based in Bethesda, Md., will use ScriptPro’s robotic dispensing, pharmacy management and drug information systems to assist in the internal control and identification of drugs and to enhance the safety and efficiency of medication dispensing and use by patients.
ScriptPro already provides pharmacy automation systems to the Veterans Health Administration, the Food and Drug Administration, the Department of Defense, federal prisons and public health services, the company said.
SIGIS updates Eligible Products List
SAN RAMON, Calif. The Special Interest Group for IIAS Standards announced Wednesday that the group is making significant changes to its Eligible Products List — a list of over-the-counter products eligible for reimbursement under flexible spending accounts — in response to IRS guidance issued earlier this month.
That guidance, issued by the IRS in Notice 2010-59 in response to changes made by the Affordable Care Act, requires a doctor’s prescription for the reimbursement of over-the-counter drug and medicines from health plans and tax-advantaged healthcare accounts.
Based on this IRS guidance, the SIGIS Eligible Products List committee completed a thorough review of the list and determined that just more than 15,000 items are impacted and will need to be removed. Even after this significant reduction, more than 27,000 OTC items remain on the list for purchase without a prescription and through a Health Care Debit Card at SIGIS-certified merchants without the need for further substantiation. Items that continue to be eligible without a prescription include such items as insulin, medical devices (crutches, blood sugar monitors, etc.), bandages, contact lens solution and denture bond.
Though the IRS rule goes into effect on Jan. 1, 2011, SIGIS is releasing a summary of the edits to help SIGIS members begin to prepare for this significant change, the group noted. The detailed SIGIS Eligible Products List will be published on Dec. 15. In the guidance, the IRS granted transitional relief for IIAS merchants, so that IIAS merchants will actually have until Jan. 15, 2011, to update their systems to be compliant with the new guidance.
The following categories have been removed from the Eligible Products List to prevent them from being purchased at an IIAS merchant without a prescription. Categories no longer eligible without a prescription include:
- Acid controllers;
- Allergy and sinus medicine;
- Antigas products;
- Anti-itch and insect bite products;
- Antiparasitic treatments;
- Baby rash ointments/creams;
- Cold sore remedies;
- Cough-cold and flu products;
- Digestive aids;
- Feminine antifungal/anti-itch products;
- Hemorrhoidal preps;
- Motion sickness products;
- Pain relievers;
- Respiratory treatments;
- Sleep aids and sedatives; and
- Stomach remedies.
SIGIS was formed to create a standard industry solution that could be both scaleable and broadly adoptable, while being consistent with IRS requirements. The group includes all stakeholders involved with the process, from pharmacy merchants through plan administrators.